Ovarian carcinoma (high-grade serous predominant) · line 2 · Olaparib maintenance (HRD+ ovarian post-platinum response)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	aggressive
Linked regimen	`REG-OLAPARIB-MAINT-OVARIAN`

ID	`IND-OVARIAN-MAINT-PARPI-BRCAM-OLAPARIB`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-OVARIAN`
Sources	`SRC-ESMO-OVARIAN-2024` `SRC-NCCN-OVARIAN-2025` `SRC-SOLO2-PUJADE-LAURAINE-2017`

Notes

ESCAT IA. BRCA-mutant 2L+ maintenance — most-evidence PARPi (SOLO2). Plan-track aggressive because adds significant PFS/OS over no maintenance.

Used By

Algorithms

ALGO-OVARIAN-2L - ALGO-OVARIAN-2L

Handbook Chapters

HB-OVARIAN-MAINTENANCE-1L - Advanced ovarian cancer: HRD/BRCA first-line maintenance reasoning

Handbook Questions

HQ-OVARIAN-MAINTENANCE-1L-001 - HQ-OVARIAN-MAINTENANCE-1L-001

Indication

IND-OVARIAN-2L-PLAT-SENS-CARBO-GEM-BEV - IND-OVARIAN-2L-PLAT-SENS-CARBO-GEM-BEV
IND-OVARIAN-2L-PLAT-SENS-CARBO-PLD-BEV - IND-OVARIAN-2L-PLAT-SENS-CARBO-PLD-BEV